• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
20
May
2016

Genentech Enters the PD-L1 Arena, Theranos in Ashes & the ASCO PR Machine Revs Up

/
Luke Timmerman
/
0
/
All
20 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
May
2016

I-O: Who’s Doing What? (Part 2)

/
Luke Timmerman
/
0
/
All, Cancer, Drugs
19 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
May
2016

Immuno-Oncology: Who’s Doing What?

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
16 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
May
2016

John Oliver’s Rant, the Sid Mukherjee Tempest & A Lung Cancer Mea Culpa

/
Luke Timmerman
/
0
/
All, Drugs
13 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
May
2016

How Distributed R&D Could Spark Entrepreneurship in Biopharma

/
Kyle Serikawa
/
0
/
All, Drugs, Politics
11 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
May
2016

Bull Market or Bubble? Watch My Chat with Biotech Leaders at Milken Global

/
Luke Timmerman
/
0
/
All, Drugs, Payers, Politics
09 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
May
2016

Prince Puts a Face on Opioids, IMS Buys Quintiles & Sarepta Running Wild

/
Luke Timmerman
/
0
/
All
06 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
May
2016

How Much Scrutiny is Biopharma Facing? Not as Much as You Might Think

/
Luke Timmerman
/
0
/
All, Politics, The Edge
02 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
Apr
2016

Congress Slaughters Hogs, Sarepta’s Bad Day & Soon-Shiong’s 9-Figure Payday

/
Luke Timmerman
/
0
/
All
29 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
Apr
2016

Theranos May Be The Trigger That Brings Order to the Diagnostic Wild West

/
Luke Timmerman
/
2
/
All, Diagnostics, The Edge
25 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Apr
2016

Sarepta in the Lion’s Den, Theranos Hits Bottom, & Pharma’s Microbiome Foray

/
Luke Timmerman
/
0
/
All
22 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Apr
2016

Less Disruption Please!

/
Lisa Suennen
/
5
/
All
20 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Apr
2016

See the Photos from the TR Anniversary Party in Boston

/
Luke Timmerman
/
0
/
All
19 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
Apr
2016

Fantasy Drug Development Leagues: Why Should Baseball Geeks Have All The Fun?

/
Kyle Serikawa
/
3
/
All, Drugs
18 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
15
Apr
2016

Medivation Stiffs Sanofi, IMS on Drug Spending, & Billionaire Worship

/
Luke Timmerman
/
0
/
All
15 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Apr
2016

12 VCs Who Matter, But You Never Read About

/
Luke Timmerman
/
4
/
All, People, Venture Capital
11 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
Apr
2016

PfizerGan Unravels, Gilead Gets NASH Drug, & Verily Self-Dealing

/
Luke Timmerman
/
0
/
All
08 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Apr
2016

Seattleites: Join Chad and Harlan Robins for an Interview at the TR Anniversary Apr. 25

/
Luke Timmerman
/
0
/
All
07 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
4
Apr
2016

How Can Migraine Drugmakers Avoid the PCSK9 Debacle?

/
Luke Timmerman
/
0
/
All, Drugs, Payers
04 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
Apr
2016

Medivation Under the Microscope, Obama’s Opioid Plan, & Burrill’s Ban

/
Luke Timmerman
/
1
/
All, Drugs
01 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 69 70 71 72 73 … 80 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder